Indicators
Indicators
Value
Direction
MACD(12,26,9)
-2.891
Neutral
RSI(14)
44.297
Neutral
STOCH(KDJ)(9,3,3)
16.461
Oversold
ATR(14)
4.575
High Vlolatility
CCI(14)
-143.924
Sell
Williams %R
79.145
Sell
TRIX(12,20)
0.140
Sell
StochRSI(14)
29.598
Buy
Neurocrine Biosciences Inc
NBIX145.000USD
+3.160+2.23%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
14.46BMarket Cap
33.69P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Neurocrine Biosciences Inc
Currency: USD Updated: 2025-12-19Key Insights
Neurocrine Biosciences Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 34/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 175.91.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Neurocrine Biosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
29
analysts
Buy
Current Rating
175.909
Target Price
+13.50%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Neurocrine Biosciences Inc Highlights
StrengthsRisks
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 58.21% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.36B.
Undervalued
The company’s latest PE is 33.69, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 101.04M shares, decreasing 2.13% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 1.84K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-19The current financial score of Neurocrine Biosciences Inc is 8.73, ranking 39/158 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 794.90M, representing a year-over-year increase of 27.78%, while its net profit experienced a year-over-year increase of 61.40%.
Score
Financials
7.62
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.37
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.65
Neurocrine Biosciences Inc's Company Valuation
Currency: USD Updated: 2025-12-19The current valuation score of Neurocrine Biosciences Inc is 5.24, ranking 151/158 in the Pharmaceuticals industry. Its current P/E ratio is 33.69, which is 359.07% below the recent high of 154.68 and 14.64% above the recent low of 28.76.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 34/158
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-19The current earnings forecast score of Neurocrine Biosciences Inc is 8.48, ranking 33/158 in the Pharmaceuticals industry. The average price target for Neurocrine Biosciences Inc is 179.00, with a high of 203.00 and a low of 146.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
29
analysts
Buy
Current Rating
175.909
Target Price
+13.50%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Neurocrine Biosciences Inc
NBIX
29
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
AbbVie Inc
ABBV
32
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-19The current price momentum score of Neurocrine Biosciences Inc is 7.07, ranking 90/158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 157.03 and the support level at 136.12, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
146.268
Sell
MA10
150.453
Sell
MA20
149.997
Sell
MA50
145.874
Sell
MA100
141.525
Buy
MA200
129.689
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-19The current institutional shareholding score of Neurocrine Biosciences Inc is 10.00, ranking 1/158 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 101.34%, representing a quarter-over-quarter increase of 2.24%. The largest institutional shareholder is The Vanguard, holding a total of 9.66M shares, representing 9.69% of shares outstanding, with 3.12% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
JP Morgan Asset Management
AQR Capital Management, LLC
Geode Capital Management, L.L.C.
Wellington Management Company, LLP
1
2
Risk Assessment
Currency: USD Updated: 2025-12-19The current risk assessment score of Neurocrine Biosciences Inc is 8.88, ranking 23/158 in the Pharmaceuticals industry. The company's beta value is 0.29. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.29
VaR
+2.84%
240-Day Maximum Drawdown
+42.89%
240-Day Volatility
+41.46%
Return
Best Daily Return
60 days
+7.37%
120 days
+7.37%
5 years
+11.07%
Worst Daily Return
60 days
-6.35%
120 days
-6.35%
5 years
-18.87%
Sharpe Ratio
60 days
+0.03
120 days
+1.12
5 years
+0.44
Risk Assessment
Maximum Drawdown
240 days
+42.89%
3 years
+42.89%
5 years
+42.89%
Return-to-Drawdown Ratio
240 days
+0.14
3 years
+0.31
5 years
+0.23
Skewness
240 days
-1.81
3 years
-1.91
5 years
-1.20
Volatility
Realised Volatility
240 days
+41.46%
5 years
+36.32%
Standardised True Range
240 days
+2.67%
5 years
+2.25%
Downside Risk-Adjusted Return
120 days
+145.70%
240 days
+145.70%
Maximum Daily Upside Volatility
60 days
+26.64%
Maximum Daily Downside Volatility
60 days
+27.04%
Liquidity
Average Turnover Rate
60 days
+0.88%
120 days
+1.21%
5 years
--
Turnover Deviation
20 days
-18.15%
60 days
-11.27%
120 days
+22.28%
Peer Comparison
Pharmaceuticals
Neurocrine Biosciences Inc
NBIX
7.97 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
ANI Pharmaceuticals Inc
ANIP
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Neurocrine Biosciences Inc?
The TradingKey Stock Score provides a comprehensive assessment of Neurocrine Biosciences Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Neurocrine Biosciences Inc’s performance and outlook.
How do we generate the financial health score of Neurocrine Biosciences Inc?
To generate the financial health score of Neurocrine Biosciences Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Neurocrine Biosciences Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Neurocrine Biosciences Inc.
How do we generate the company valuation score of Neurocrine Biosciences Inc?
To generate the company valuation score of Neurocrine Biosciences Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Neurocrine Biosciences Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Neurocrine Biosciences Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Neurocrine Biosciences Inc.
How do we generate the earnings forecast score of Neurocrine Biosciences Inc?
To calculate the earnings forecast score of Neurocrine Biosciences Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Neurocrine Biosciences Inc’s future.
How do we generate the price momentum score of Neurocrine Biosciences Inc?
When generating the price momentum score for Neurocrine Biosciences Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Neurocrine Biosciences Inc’s prices. A higher score indicates a more stable short-term price trend for Neurocrine Biosciences Inc.
How do we generate the institutional confidence score of Neurocrine Biosciences Inc?
To generate the institutional confidence score of Neurocrine Biosciences Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Neurocrine Biosciences Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Neurocrine Biosciences Inc.
How do we generate the risk management score of Neurocrine Biosciences Inc?
To assess the risk management score of Neurocrine Biosciences Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Neurocrine Biosciences Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Neurocrine Biosciences Inc.
